JP2022537158A5 - - Google Patents
Info
- Publication number
- JP2022537158A5 JP2022537158A5 JP2021573841A JP2021573841A JP2022537158A5 JP 2022537158 A5 JP2022537158 A5 JP 2022537158A5 JP 2021573841 A JP2021573841 A JP 2021573841A JP 2021573841 A JP2021573841 A JP 2021573841A JP 2022537158 A5 JP2022537158 A5 JP 2022537158A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- peg
- pep
- heteroaryl
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076031A JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861139P | 2019-06-13 | 2019-06-13 | |
| US62/861,139 | 2019-06-13 | ||
| US202062963884P | 2020-01-21 | 2020-01-21 | |
| US62/963,884 | 2020-01-21 | ||
| PCT/US2020/037477 WO2020252294A1 (en) | 2019-06-13 | 2020-06-12 | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076031A Division JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537158A JP2022537158A (ja) | 2022-08-24 |
| JP2022537158A5 true JP2022537158A5 (https=) | 2023-06-16 |
Family
ID=71608047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573841A Ceased JP2022537158A (ja) | 2019-06-13 | 2020-06-12 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
| JP2025076031A Pending JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076031A Pending JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200390899A1 (https=) |
| EP (1) | EP3983082A1 (https=) |
| JP (2) | JP2022537158A (https=) |
| KR (1) | KR20220034784A (https=) |
| CN (1) | CN114585390A (https=) |
| AU (1) | AU2020291014B2 (https=) |
| BR (1) | BR112021025034A2 (https=) |
| CA (1) | CA3142887A1 (https=) |
| IL (1) | IL288816A (https=) |
| MX (1) | MX2021015221A (https=) |
| TW (1) | TW202112752A (https=) |
| WO (1) | WO2020252294A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20220347310A1 (en) * | 2019-09-30 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| TWI857167B (zh) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
| JP2023511362A (ja) * | 2020-01-21 | 2023-03-17 | ボルト バイオセラピューティクス、インコーポレーテッド | 坑ｐｄ－ｌ１抗体 |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| US20230293716A1 (en) * | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| IL300316A (en) * | 2020-08-13 | 2023-04-01 | Bolt Biotherapeutics Inc | Immune conjugates of pyrazolozapines and their uses |
| CA3200056A1 (en) * | 2020-12-11 | 2022-06-16 | Shelley Erin ACKERMAN | Anti-her2 immunoconjugates, and uses thereof |
| CA3200168A1 (en) * | 2020-12-11 | 2022-06-16 | Shelley Erin ACKERMAN | Anti-pd-l1 immunoconjugates, and uses thereof |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| CN116635084A (zh) * | 2020-12-11 | 2023-08-22 | 博尔特生物治疗药物有限公司 | 抗cea免疫缀合物和其用途 |
| CN116897054A (zh) * | 2020-12-11 | 2023-10-17 | 博尔特生物治疗药物有限公司 | 抗her2免疫缀合物及其用途 |
| WO2022155503A1 (en) * | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| CN117769439A (zh) * | 2021-03-26 | 2024-03-26 | 博尔特生物治疗药物有限公司 | 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途 |
| CN117940168A (zh) * | 2021-03-26 | 2024-04-26 | 博尔特生物治疗药物有限公司 | 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途 |
| AU2022279185A1 (en) * | 2021-05-19 | 2024-01-04 | Shanghai De Novo Pharmatech Co., Ltd. | Nitrogen-containing compound, conjugate containing said compound, and application thereof |
| CA3222082A1 (en) * | 2021-06-25 | 2022-12-29 | Gary Brandt | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof |
| JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| EP4450496A4 (en) * | 2021-12-16 | 2025-12-24 | Duality Biologics Suzhou Co Ltd | TLR MODULATOR AND ITS USAGE |
| EP4475892A1 (en) * | 2022-02-09 | 2024-12-18 | Bolt Biotherapeutics, Inc. | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses |
| TW202339806A (zh) * | 2022-02-09 | 2023-10-16 | 美商博特生物治療公司 | ８—磺醯基—苯并氮呯免疫結合物及其用途 |
| CN119233973A (zh) * | 2022-06-02 | 2024-12-31 | 映恩生物制药（苏州）有限公司 | 一种药物化合物及其用途 |
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| NZ507557A (en) | 1998-05-06 | 2003-10-31 | Genentech Inc | Protein purification by ion exchange chromatography |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| DK2532680T3 (da) | 2010-02-04 | 2015-07-20 | Toray Industries | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| PL2740793T3 (pl) | 2011-08-04 | 2018-04-30 | Toray Industries, Inc. | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi |
| EP2740794B1 (en) | 2011-08-04 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| ES2739612T3 (es) | 2012-02-21 | 2020-02-03 | Toray Industries | Composición farmacéutica para el tratamiento de cáncer |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| MX357292B (es) | 2012-07-19 | 2018-07-04 | Toray Industries | Método para detectar cáncer. |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| JP6644792B2 (ja) * | 2014-12-18 | 2020-02-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンザゼピンスルホンアミド化合物 |
| PT3265458T (pt) * | 2015-03-06 | 2019-02-13 | Hoffmann La Roche | Compostos de dicarboxamida de benzazepina |
| MX383893B (es) * | 2015-11-02 | 2025-03-14 | Ventirx Pharmaceuticals Inc | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer. |
| JP6918838B2 (ja) * | 2016-05-23 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| CN109311854B (zh) * | 2016-05-23 | 2021-08-10 | 豪夫迈·罗氏有限公司 | 具有仲酰胺官能团的苯并氮杂卓二甲酰胺化合物 |
| JP7012668B2 (ja) * | 2016-06-12 | 2022-02-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 |
| CN109890417A (zh) | 2016-10-28 | 2019-06-14 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| US20190336615A1 (en) * | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| SG10202110182PA (en) * | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| JP2021506827A (ja) * | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
| MX2021002764A (es) * | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| AU2019337654A1 (en) * | 2018-09-12 | 2021-04-08 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
-
2020
- 2020-06-12 US US16/900,193 patent/US20200390899A1/en not_active Abandoned
- 2020-06-12 BR BR112021025034A patent/BR112021025034A2/pt unknown
- 2020-06-12 WO PCT/US2020/037477 patent/WO2020252294A1/en not_active Ceased
- 2020-06-12 JP JP2021573841A patent/JP2022537158A/ja not_active Ceased
- 2020-06-12 KR KR1020227001083A patent/KR20220034784A/ko active Pending
- 2020-06-12 AU AU2020291014A patent/AU2020291014B2/en active Active
- 2020-06-12 CN CN202080053101.9A patent/CN114585390A/zh active Pending
- 2020-06-12 CA CA3142887A patent/CA3142887A1/en active Pending
- 2020-06-12 MX MX2021015221A patent/MX2021015221A/es unknown
- 2020-06-12 TW TW109119949A patent/TW202112752A/zh unknown
- 2020-06-12 EP EP20740106.8A patent/EP3983082A1/en active Pending
-
2021
- 2021-12-09 IL IL288816A patent/IL288816A/en unknown
-
2025
- 2025-05-01 JP JP2025076031A patent/JP2025118748A/ja active Pending
- 2025-05-09 US US19/203,992 patent/US20250263392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537158A5 (https=) | ||
| JP2022553702A5 (https=) | ||
| JP2022549510A5 (https=) | ||
| JP2023002615A5 (https=) | ||
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| RU2503687C2 (ru) | Сшивающие реагенты и их применение | |
| JP2023547323A5 (https=) | ||
| JP2023524271A5 (https=) | ||
| JP2022512778A5 (https=) | ||
| JP2019520352A5 (https=) | ||
| JP2024545233A5 (https=) | ||
| JP2019532056A5 (https=) | ||
| JP2017518304A5 (https=) | ||
| JP2024523453A5 (https=) | ||
| JP2018516243A5 (https=) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| US20230295346A1 (en) | Prodruggable antibodies, prodrugs thereof, and methods of use and making | |
| JP2023553421A5 (ja) | 抗ｃｅａ免疫複合体、及びその使用 | |
| JP2024521921A5 (https=) | ||
| JP2018511628A5 (https=) | ||
| JP2024546497A5 (https=) | ||
| RU2019122802A (ru) | Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы | |
| JP2021527640A5 (https=) | ||
| JP2022514949A5 (https=) | ||
| JP2022546110A5 (https=) |